Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galapagos Eyes Rare European Biotech Heavyweight Title, Launches $338m Offering

Executive Summary

Galapagos is seeking $338m via a US public offering to fund Phase III studies for its lead drug filgotinib in various new immunology and inflammation indications. The biotech will also use the cash to prepare for its evolution into a commercial organization in the next few years, when it hopes to start promoting the drug in Europe for the treatment of rheumatoid arthritis. Ultimately it wants to be a major European biotech leader.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts